Study to Evaluate the Reliability and Validity of the Modified Manual Muscle Test for Persons With MS

NCT ID: NCT03603691

Last Updated: 2019-01-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-01

Study Completion Date

2019-01-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Many patients with multiple sclerosis (MS) are treated with physiotherapy. Muscle weakness is a common symptom. It can be evaluated with a variety of muscle function tests. In MS patients, testing muscle function can be confounded by many factors, such as spasticity and ataxia, which are not considered by the existing tests and may cause biased test results. Steinlin Egli described a Modified Manual Muscle Test (MMMT) that considers spasticity and may provide a more reliable and valid muscle function test for MS patients.

The investigators aim to evaluate the inter- and intra-rater reliability of the Modified Manual Muscle Test in MS and evaluate the validity of the Modified MMT according to the criteria of the 6 level British Medical Research Council (BMRC) manual muscle test and the microFET2 handhold dynamometer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background In Switzerland, many patients with multiple sclerosis (MS) are treated with physiotherapy. Muscle weakness is a common symptom. Particularly in progressive disease courses, motor dysfunction is a major contributor to the reduced mobility and quality of life. Therefore, improving the motor dysfunction is an important goal for therapy and is evaluated with a variety of muscle function tests. The 6 level British Medical Research Council (BMRC) manual muscle test is the most widely used test in MS and is a part of the Neurostatus-Expanded Disability Status Scale (EDSS) assessment, which has been adopted as the standard in most of the pivotal trials that have led to the approval of the current MS treatments. In MS patients, testing muscle function can be confounded by many factors, such as spasticity and ataxia, which are not considered by the existing tests and may cause biased test results. Steinlin Egli described a Modified Manual Muscle Test (MMMT) that considers spasticity and may provide a more reliable and valid muscle function test for MS patients.

Aim of the study is to evaluate the inter- and intra-rater reliability of the Modified Manual Muscle Test in MS and evaluate the validity of the Modified MMT according to the criteria of the Neurostatus BMRC manual muscle test and the microFET2 handhold dynamometer.

Methods This is a single-centre, prospective cross-sectional study with a test-retest design. The Neurostatus BMRC manual muscle test and the microFET2 hand held dynamometer are used as the criteria. The primary endpoint is the ordinal MMMT level. The intra-class correlation coefficient (ICC) of the ranked MMMT levels will be estimated. The investigator aims to show that the MMMT results are clinically relevant with a high level of ICC.

The secondary endpoints include the Neurostatus BMRC levels, the muscle strength as measured by the microFET2 dynamometer and fatigue using a numeric rating scale (NRS). Subgroup analyses will determine whether the MMMT is less sensitive to the influence of spasticity than the Neurostatus BMRC.

28 patients with MS will be tested in 2 days. In each day, six examiners will test seven patients in the morning and seven patients in the afternoon. Three MS-therapists from the Specialized Group Physiotherapy in MS and three neurologists from the Department of Neurology at the University Hospital Basel will be tester. All examiners will be blinded to the results of the other examiners. All test persons will be blinded to their test results. First, the patient will rate his fatigue using the NRS. Muscle function will be tested with the microFET2 and spasticity will be assessed using the modified Tardieu Scale. Then, the first round of manual testing will be executed. After each test, there will be a break that is long enough for the patients to recuperate. The order of the examiners will be randomized. The retest round will proceed in a different order. Finally, spasticity will be tested again using the modified Tardieu Scale, and the patients will rate their fatigue.

Statistical Analysis The study data will be analysed using the internet-based program R. The descriptive statistics will describe the sample characteristics. The inter-rater reliability will be estimated by the ICC of the MMMT ranks. The ICC will be estimated by a two-way random-effects ANOVA and reported with 95% CI. If the lower limit of the CI is larger than the pre-specified clinically relevant ICC margin, the MMMT will be considered a reliable tool for evaluating muscle strength in MS patients.

The inter-rater reliability the Neurostatus BMRC will be estimated similarly by the ICC. The ICC of both tests will be compared. The test-retest reliability of the MMMT and Neurostatus BMRC will be estimated using two-way random-effects ANOVA and will be reported by ICC estimates. The influence of potential fatigue will be analysed by plotting the test and retest results against the NRS and investigating the associations and interactions using a linear mixed effects model. The pairwise correlations of the MMMT and the Neurostatus BMRC with the microFET2 will be graphically analysed (scatterplots and/or boxplots), and Spearman's ρ will be calculated. The primary and secondary analyses will be repeated for subgroups with high and low spasticity patients to compare the sensitivity of the MMMT and Neurostatus BMRC to spasticity.

Expected results: The investigators expect the MMMT for MS to be a reliable and valid manual muscle function test that can be used in the evaluation of the long-term treatment of MS patients with physical therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Prospective, cross-sectional and test-retest
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Outcome Assessors
the outcome assessors will be blinded for the results of other assessors.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Modified Manual Muscle Test

The MMMT will be tested in a test-retest design

Group Type ACTIVE_COMPARATOR

Modified Manual Muscle Test

Intervention Type DIAGNOSTIC_TEST

Manual Muscle Testing Grading System from 0=No visible or palpable contraction to 5= full range of movement against gravity, maximal resistance

BMRC manual muscle test

Intervention Type DIAGNOSTIC_TEST

muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle

MicroFET2 handhold dynamometer

Intervention Type DIAGNOSTIC_TEST

MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various muscle groups

Modified Tardieu Scale

Intervention Type DIAGNOSTIC_TEST

Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement

Fatigue Scale for Motor and Cognitive Functions

Intervention Type DIAGNOSTIC_TEST

Measures cognitive and motor fatigue for people with MS

numeric rating scale Fatigue

Intervention Type DIAGNOSTIC_TEST

visual analog scale that uses a scalar numbering system to objectify a patient's fatigue (0 = no fatigue; 10 = most extreme fatigue)

Neurostatus BMRC

The Neurostatus BMRC measures Strength and will be used in a test-retest design

Group Type ACTIVE_COMPARATOR

Modified Manual Muscle Test

Intervention Type DIAGNOSTIC_TEST

Manual Muscle Testing Grading System from 0=No visible or palpable contraction to 5= full range of movement against gravity, maximal resistance

BMRC manual muscle test

Intervention Type DIAGNOSTIC_TEST

muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle

MicroFET2 handhold dynamometer

Intervention Type DIAGNOSTIC_TEST

MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various muscle groups

Modified Tardieu Scale

Intervention Type DIAGNOSTIC_TEST

Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement

Fatigue Scale for Motor and Cognitive Functions

Intervention Type DIAGNOSTIC_TEST

Measures cognitive and motor fatigue for people with MS

numeric rating scale Fatigue

Intervention Type DIAGNOSTIC_TEST

visual analog scale that uses a scalar numbering system to objectify a patient's fatigue (0 = no fatigue; 10 = most extreme fatigue)

MicroFET2

The MicroFET2 is a hand held dynamometer to measure strength

Group Type ACTIVE_COMPARATOR

Modified Manual Muscle Test

Intervention Type DIAGNOSTIC_TEST

Manual Muscle Testing Grading System from 0=No visible or palpable contraction to 5= full range of movement against gravity, maximal resistance

BMRC manual muscle test

Intervention Type DIAGNOSTIC_TEST

muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle

MicroFET2 handhold dynamometer

Intervention Type DIAGNOSTIC_TEST

MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various muscle groups

Modified Tardieu Scale

Intervention Type DIAGNOSTIC_TEST

Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement

Fatigue Scale for Motor and Cognitive Functions

Intervention Type DIAGNOSTIC_TEST

Measures cognitive and motor fatigue for people with MS

numeric rating scale Fatigue

Intervention Type DIAGNOSTIC_TEST

visual analog scale that uses a scalar numbering system to objectify a patient's fatigue (0 = no fatigue; 10 = most extreme fatigue)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Modified Manual Muscle Test

Manual Muscle Testing Grading System from 0=No visible or palpable contraction to 5= full range of movement against gravity, maximal resistance

Intervention Type DIAGNOSTIC_TEST

BMRC manual muscle test

muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle

Intervention Type DIAGNOSTIC_TEST

MicroFET2 handhold dynamometer

MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various muscle groups

Intervention Type DIAGNOSTIC_TEST

Modified Tardieu Scale

Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement

Intervention Type DIAGNOSTIC_TEST

Fatigue Scale for Motor and Cognitive Functions

Measures cognitive and motor fatigue for people with MS

Intervention Type DIAGNOSTIC_TEST

numeric rating scale Fatigue

visual analog scale that uses a scalar numbering system to objectify a patient's fatigue (0 = no fatigue; 10 = most extreme fatigue)

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosed with MS according to the McDonald criteria
* EDSS between 0 and 6.5
* older than 18 years of age.

Exclusion Criteria

* An acute episode of MS within 3 months prior to the testing,
* grave cognitive changes
* distinct fatigue
* a history of current back, neck or elbow pain
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Basel, Switzerland

OTHER

Sponsor Role collaborator

Physiotherapie Langmatten Binningen, Switzerland

UNKNOWN

Sponsor Role collaborator

Clinical Trial Unit, University Hospital Basel, Switzerland

OTHER

Sponsor Role collaborator

Nanco van der Maas

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nanco van der Maas

Principle Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nico van der Maas

Role: PRINCIPAL_INVESTIGATOR

Institute for Physiotherapy Research, Biel, Switzerland

Marcus Dsouza, Dr. med.

Role: PRINCIPAL_INVESTIGATOR

University Hospital Basle, Basle, Switzerland

Regula Steinlin Egli

Role: PRINCIPAL_INVESTIGATOR

Specialized Group Physiotherapy in MS, Binningen, Switzerland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Felix Platter Hospital

Basel, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-01103; me16Kappos3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

VR-based Dexterity Training in MS
NCT07193602 NOT_YET_RECRUITING NA
MSPT Device Usability Study
NCT02664324 COMPLETED